A randomised study of the effect of danoprevir/ritonavir or ritonavir on substrates of cytochrome P450 (CYP) 3A and 2C9 in chronic hepatitis C patients using a drug cocktail

European Journal of Clinical Pharmacology

Volumn 69, Issue 11, 2013, Pages 1939-1949

  Morcos, Peter N ^a   Chang, Linda ^a,e   Kulkarni, Rohit ^b   Giraudon, Mylene ^c   Shulman, Nancy ^d   Brennan, Barbara J ^a   Smith, Patrick F ^a,f,g   Tran, Jonathan Q ^a,h  

^a HOFFMANN LA ROCHE INC   (United States)

^b Guardian Analytics   (United States)

^c F HOFFMANN LA ROCHE LTD   (Switzerland)

^d GENENTECH INC   (United States)

^e MEDIMMUNE   (United States)

^f D3 Limited   (United States)

^g UNIVERSITY AT BUFFALO   (United States)

^h BIOGEN   (United States)

Author keywords

CYP3A; Danoprevir; Midazolam; Ritonavir; Warfarin

Indexed keywords

ALPHA HYDROXYMIDAZOLAM; CYTOCHROME P450 2C9; CYTOCHROME P450 3A; DANOPREVIR; MIDAZOLAM; PLACEBO; RITONAVIR; VITAMIN K GROUP; WARFARIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG INHIBITION; DRUG METABOLISM; DRUG MIXTURE; DRUG POTENTIATION; ENZYME INDUCTION; ENZYME INHIBITION; FEMALE; HEPATITIS C; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; ANTIVIRAL AGENTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HEPATITIS C, CHRONIC; HUMANS; LACTAMS; MALE; MIDAZOLAM; MIDDLE AGED; RITONAVIR; SULFONAMIDES; VITAMIN K; WARFARIN; YOUNG ADULT;

EID: 84886794737     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-013-1556-y     Document Type: Article

References (37)

1. Marcellin P, Roberts SK, Reddy KR, Harrison SA, Jensen DM, Hadziyannis S, Diago M, Weltman M, Messinger D, Tatsch F, Rizzetto M (2012) Safety profile of standard- vs. high-dose peginterferon alfa-2a plus standard-dose ribavirin in HCV genotype 1/4 patients: pooled analysis from 5 randomized studies. Expert Opin Drug Saf 11(6):901-909
2. Brennan BJ, Xu ZX, Grippo J (2013) Effect of peginterferon alfa-2a (40KD) on cytochrome P450 isoenzyme activity. Br J Clin Pharmacol 75(2):497-506
3. Gupta SK, Kolz K, Cutler DL (2011) Effects of multiple-dose pegylated interferon alfa-2b on the activity of drug-metabolizing enzymes in persons with chronic hepatitis C. Eur J Clin Pharmacol 67(6):591-599
4. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB, American Association for Study of Liver Diseases (2011) An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 54(4):1433-1444
5. Vertex Pharmaceuticals (2012) Incivek prescribing information. Vertex Pharmaceuticals, Cambridge. Available at: http://pi.vrtx.com/files/uspi- telaprevir.pdf. Accessed 23 July 2012
6. Merck & Co. Inc. (2012) Victrelis prescribing information. Merck & Co. Inc., Whitehouse Station. Available at: http://www.merck.com/product/ usa/pi-circulars/v/victrelis/victrelis-pi.pdf. Accessed 23 July 2012
7. Kiser JJ, Burton JR, Anderson PL, Everson GT (2012) Review and management of drug interactions with boceprevir and telaprevir. Hepatology 55:1620-1628
8. Rajagopalan R, Misialek S, Stevens SK, Myszka DG, Brandhuber BJ, Ballard JA, Andrews SW, Seiwert SD, Kossen K (2009) Inhibition and binding kinetics of the hepatitis C virus NS3 protease inhibitor ITMN-191 reveals tight binding and slow dissociative behavior. Biochemistry 48(11):2559-2568
9. Seiwert SD, Andrews SW, Jiang Y, Serebryany V, Tan H, Kossen K, Rajagopalan PT, Misialek S, Stevens SK, Stoycheva A, Hong J, Lim SR, Qin X, Rieger R, Condroski KR, Zhang H, Do MG, Lemieux C, Hingorani GP, Hartley DP, Josey JA, Pan L, Beigelman L, Blatt LM (2008) Preclinical characteristics of the hepatitis C virus NS3/4A protease inhibitor ITMN-191 (R7227). Antimicrob Agents Chemother 52(12):4432-4441
10. Everson G, Cooper C, Hezode C, Shiffman ML, Yoshida E, Beltran-Jaramillo T, Ferenci P, Zeuzem S, Brunda M, Shulman N, Navarro MT, Voulgari A, Le Pogam S, Najera I, Yetzer ES (2012) High SVR24 rates with ritonavir-boosted danoprevir plus Peg-IFNα-2a (40KD)/RBV in HCV genotype 1 or 4 patients in the DAUPHINE study. Hepatology 56(4 Suppl):552A
11. Abbott Laboratories (2011) Norvir Prescribing information. Abbott Laboratories, North Chicago. Available at: http://www.accessdata.fda.gov/ drugsatfda-docs/label/2012/020945s034lbl.pdf. Accessed 23 July 2012
12. Foisy MM, Yakiwchuk EM, Hughes CA (2008) Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother 42(7):1048-1059
13. Becker SL (2003) The role of pharmacological enhancement in protease inhibitor-based highly active antiretroviral therapy. Expert Opin Investig Drugs 12(3):401-412
14. Scott JD (2005) Simplifying the treatment of HIV infection with ritonavir-boosted protease inhibitors in antiretroviral-experienced patients. Am J Health Syst Pharm 62:809-815
15. Hill A, van der Lugt J, Sawyer W, Boffito M (2009) How much ritonavir is needed to boost protease inhibitors? Systematic review of 17 dose-ranging pharmacokinetic trials. AIDS 23:2237-2245
16. Reddy MB, Chen Y, Haznedar JO, Fretland J, Blotner S, Smith P, Tran JQ (2012) Impact of low-dose ritonavir on danoprevir pharmacokinetics: results of computer-based simulations and a clinical drug-drug interaction study. Clin Pharmacokinet 51(7):457-465
17. Goezler P, Morcos PN, Tran J, Wen B, Shulman N, Smith P, Singer T, Brennan B, Hammond J (2012) Coadministration of ritonavir with the HCV protease inhibitor danoprevir substantially reduces reactive metabolite formation both in vitro and in vivo. Hepatology 56(4 Suppl):580A
18. Morcos PN, Brennan B, Blotner S, Naidu K, Fretland J, Tran JQ (2009) The effect of R7227 (ITMN-191), a novel hepatitis C virus (HCV) protease inhibitor on the pharmacokinetics (PK) of midazolam, a sensitive CYP3A4 probe substrate, in healthy volunteers. In: 4th Int Workshop on Clinical Pharmacology of Hepatitis Therapy. Abstract 8. Boston
19. Zhou H, Tong Z, McLeod JF (2004) "Cocktail" approaches and strategies in drug development: valuable tool or flawed science? J Clin Pharmacol 44(2):120-134
20. Kuhlmann J, Mück W (2001) Clinical-pharmacological strategies to assess drug interaction potential during drug development. Drug Saf 24(10):715-725
21. Gane EJ, Rouzier R, Stedman C, Wiercinska-Drapalo A, Horban A, Chang L, Zhang Y, Sampeur P, Nájera I, Smith P, Shulman NS, Tran JQ (2011) Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN α-2a/RBV in hepatitis C patients. J Hepatol 55(5):972-979
22. Gane EJ, Rouzier R, Wiercinska-Drapalo A, Larrey DG, Bhardwaj R, Brennan BJ, Giraudon M, Le Pogam S, Nájera I, Petric R, Tran JQ, Kulkarni R, Zhang Y, Smith P, Yetzer ES, Shulman NS (2012) Sustained virological response (SVR) rate of 67% in HCV genotype 1-infected prior null responders treated with danoprevir/ritonavir (DNVr) in combination with peginterferon alfa-2a (40KD) plus ribavirin (PegIFN α-2a/RBV). Hepatology 56(4 Suppl):558A
23. US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) (2012) Guidance for industry: drug interaction studies - study design, data analysis, implications for dosing, and labeling recommendations. Available at: http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM292362.pdf. Accessed 12 June 2012
24. Bristol-Myers Squibb Co. (2011) Coumadin prescribing information. Bristol-Myers Squibb Co., Princeton. Available at: http://packageinserts.bms. com/pi/pi-coumadin.pdf. Accessed 23 July 2012
25. Turpault S, Brian W, Van Horn R, Santoni A, Poitiers F, Donazzolo Y, Boulenc X (2009) Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A. Br J Clin Pharmacol 68(6):928-935
26. Pentikäinen PJ, Välisalmi L, Himberg JJ, Crevoisier C (1989) Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. J Clin Pharmacol 29(3):272-277
27. Guzmán-Fulgencio M, Jiménez JL, Berenguer J, Fernández-Rodríguez A, López JC, Cosín J, Miralles P, Micheloud D, Muñoz-Fernández MÁ, Resino S (2012) Plasma IL-6 and IL-9 predict the failure of interferon-α plus ribavirin therapy in HIV/HCV-coinfected patients. J Antimicrob Chemother 67(5):1238-1245
28. Ueyama M, Nakagawa M, Sakamoto N, Onozuka I, Funaoka Y, Watanabe T, Nitta S, Kiyohashi K, Kitazume A, Murakawa M, Nishimura-Sakurai Y, Sekine-Osajima Y, Itsui Y, Azuma S, Kakinuma S, Watanabe M, Ochanomizu-Liver Conference Study Group (2011) Serum interleukin-6 levels correlate with resistance to treatment of chronic hepatitis C infection with pegylated-interferon-α2b plus ribavirin. Antivir Ther 16:1081-1091
29. Dickmann LJ, Patel SK, Rock DA, Wienkers LC, Slatter JG (2011) Effects of interleukin-6 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture. Drug Metab Dispos 39:1415-1422
30. Aitken AE, Morgan ET (2007) Gene-specific effects of inflammatory cytokines on cytochrome P4502C, 2B6 and 3A4 mRNA levels in human hepatocytes. Drug Metab Dispos 35(9):1687-1693
31. Dumond JB, Vourvahis M, Rezk NL, Patterson KB, Tien HC, White N, Jennings SH, Choi SO, Li J, Wagner MJ, La-Beck NM, Drulak M, Sabo JP, Castles MA, Macgregor TR, Kashuba AD (2010) A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin Pharmacol Ther 87(6):735-742
32. Genentech Inc (2012) Invirase prescribing information Genentech Inc., South San Francisco. Available at: http://www.gene.com/gene/products/ information/invirase/pdf/pi.pdf. Accessed 23 July 2012
33. Yeh RF, Gaver VE, Patterson KB, Rezk NL, Baxter-Meheux F, Blake MJ, Eron JJ Jr, Klein CE, Rublein JC, Kashuba AD (2006) Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Def Syndr 42(1):52-60
34. Liptrott NJ, Owen A (2011) The role of cytokines in the regulation of drug disposition: extended functional pleiotropism? Expert Opin Drug Metab Toxicol 7(3):341-352
35. Ingelman-Sundberg M (2004) Human drug metabolising cytochrome P450 enzymes: properties and polymorphisms. Naunyn Schmiedeberg's Arch Pharmacol 369(1):89-104
36. Tomalik-Scharte D, Lazar A, Fuhr U, Kirchheiner J (2008) The clinical role of genetic polymorphisms in drug-metabolizing enzymes. Pharmacogenomics J 8:4-15
37. Shirasaka Y, Chang S-Y, Grubb MF, Peng C-C, Thummel KE, Isoherranen N, Rodrigues AD (2013) Impact of CYP3A5 expression on the inhibition of CYP3A-catalyzed drug metabolism: considerations for modelling CYP3A-mediated drug-drug interactions. Drug Metabol Dispos. doi: 10.1124/dmd.112.049940